Plus Therapeutics Secures $5.7 Million in Funding to Advance Cancer Research
#PSTV News: Plus Therapeutics has successfully closed a private placement with $3.7 million in upfront proceeds and received a $2.0 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT) as part of its existing $17.6 million grant award.
This $5.7 million in funding will accelerate the clinical development of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM)—a rare and aggressive form of metastatic cancer. Additionally, the funds will support the further development of CNSide, the Company’s LM diagnostic test, as a pivotal trial endpoint to enhance patient care and treatment evaluation.
With this strategic investment, Plus Therapeutics continues to advance its mission of developing innovative radiotherapeutics and diagnostics for central nervous system (CNS) cancers, bringing new hope to patients with limited treatment options.
🔬 Read the full Press Release: Click here
#CancerResearch #Oncology #LeptomeningealMetastases #ClinicalTrials #BrainCancer #MedicalInnovation #PSTV
Recent Comments